List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7080339/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Current and Potential Therapeutic Strategies for Hemodynamic Cardiorenal Syndrome. CardioRenal Medicine, 2016, 6, 83-98.	1.9	442
2	Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microbial Drug Resistance, 2016, 22, 412-431.	2.0	197
3	Incremental Hemodialysis, Residual Kidney Function, and Mortality Risk in Incident Dialysis Patients: A Cohort Study. American Journal of Kidney Diseases, 2016, 68, 256-265.	1.9	186
4	Current treatment practice and outcomes. Report of the hyponatremia registry. Kidney International, 2015, 88, 167-177.	5.2	149
5	The Obesity Paradox in Kidney Disease: How to Reconcile It With Obesity Management. Kidney International Reports, 2017, 2, 271-281.	0.8	124
6	Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. Journal of Hospital Medicine, 2012, 7, 231-238.	1.4	118
7	Intradialytic hypotension, blood pressure changes and mortality risk in incident hemodialysis patients. Nephrology Dialysis Transplantation, 2018, 33, 149-159.	0.7	110
8	Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers. New England Journal of Medicine, 2019, 380, 638-650.	27.0	107
9	Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Practice Guidelines for Management and Care Transitions in the Emergency Department and Hospital. Journal of Emergency Medicine, 2015, 48, 508-519.	0.7	88
10	Medical cost reductions associated with the usage of novel oral anticoagulants vs warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF, and ARISTOTLE trials. Journal of Medical Economics, 2012, 15, 776-785.	2.1	83
11	Inpatient thromboprophylaxis use in U.S. hospitals: Adherence to the seventh American College of Chest Physician's recommendations for at-risk medical and surgical patients. Journal of Hospital Medicine, 2009, 4, E15-E21.	1.4	64
12	Estimation of the impact of warfarin's time-in-therapeutic range on stroke and major bleeding rates and its influence on the medical cost avoidance associated with novel oral anticoagulant use-learnings from ARISTOTLE, ROCKET-AF, and RE-LY trials. Journal of Thrombosis and Thrombolysis, 2014–38–150-159	2.1	62
13	Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population. Current Medical Research and Opinion, 2017, 33, 1595-1604.	1.9	55
14	Evaluation of incremental healthcare resource burden and readmission rates associated with hospitalized hyponatremic patients in the US. Journal of Hospital Medicine, 2012, 7, 634-639.	1.4	47
15	Approach and Management of Hypertension After Kidney Transplantation. Frontiers in Medicine, 2020, 7, 229.	2.6	44
16	Preventing venous thromboembolism in US hospitals: Are surgical patients receiving appropriate prophylaxis?. Thrombosis and Haemostasis, 2008, 99, 796-797.	3.4	43
17	Hospitalist Perspective on the Treatment of Skin and Soft Tissue Infections. Mayo Clinic Proceedings, 2014, 89, 1436-1451.	3.0	43
18	Attitudes and Preferences on the Use of Mobile Health Technology and Health Games for Self-Management: Interviews With Older Adults on Anticoagulation Therapy. JMIR MHealth and UHealth, 2014, 2, e32.	3.7	43

#	Article	IF	CITATIONS
19	Pre-dialysis serum sodium and mortality in a national incident hemodialysis cohort. Nephrology Dialysis Transplantation, 2016, 31, 992-1001.	0.7	41
20	Clinical and Economic Consequences of Ventilatorâ€Associated Pneumonia. Clinical Infectious Diseases, 2009, 49, S36-S43.	5.8	37
21	Does ambulation modify venous thromboembolism risk in acutely ill medical patients?. Thrombosis and Haemostasis, 2010, 104, 955-961.	3.4	33
22	Current Management of Hyponatremia in Acute Heart Failure: A Report From the Hyponatremia Registry for Patients With Euvolemic and Hypervolemic Hyponatremia (HN Registry). Journal of the American Heart Association, 2017, 6, .	3.7	33
23	Confidence in correct inhaler technique and its association with treatment adherence and health status among US patients with chronic obstructive pulmonary disease. Patient Preference and Adherence, 2017, Volume 11, 1205-1212.	1.8	33
24	Implementing Critical Pathways and a Multidisciplinary Team Approach to Cardiovascular Disease Management. American Journal of Cardiology, 2008, 102, 47G-56G.	1.6	28
25	The Hospitalist Perspective on Treatment of Community–Acquired Bacterial Pneumonia. Postgraduate Medicine, 2014, 126, 18-29.	2.0	27
26	Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely III Hospitalized Medical Patients. Circulation, 2018, 137, 91-94.	1.6	27
27	Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. Journal of Medical Economics, 2015, 18, 399-409.	2.1	26
28	Optimizing the Prevention of Venous Thromboembolism: Recent Quality Initiatives and Strategies to Drive Improvement. Joint Commission Journal on Quality and Patient Safety, 2009, 35, 558-AP2.	0.7	25
29	Hospital Readmissions in US Atrial Fibrillation Patients. American Journal of Therapeutics, 2013, 20, 143-150.	0.9	25
30	Retrospective Administrative Database Study of the Time Period of Venous Thromboembolism Risk During and Following Hospitalization for Major Orthopedic or Abdominal Surgery in Real-World US Patients. Hospital Practice (1995), 2011, 39, 7-16.	1.0	24
31	Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies. Clinical Interventions in Aging, 2013, 8, 75.	2.9	24
32	Personalizing Nursing Home Compare and the Discharge from Hospitals to Nursing Homes. Health Services Research, 2016, 51, 2076-2094.	2.0	24
33	Appropriate thromboprophylaxis in hospitalized cancer patients. Clinical Advances in Hematology and Oncology, 2008, 6, 910-20.	0.3	24
34	Health Care Utilization, Costs, and Readmission Rates Associated With Hyponatremia. Hospital Practice (1995), 2013, 41, 89-95.	1.0	23
35	Direct Oral Anticoagulants for the Management of Thromboembolic Disorders. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 605-616.	1.7	23
36	Feasibility Study of a Mobile Health Intervention for Older Adults on Oral Anticoagulation Therapy. Gerontology and Geriatric Medicine, 2016, 2, 233372141667297.	1.5	23

#	Article	IF	CITATIONS
37	Mortality, Health Care Use, and Costs of Clostridioides difficile Infections in Older Adults. Journal of the American Medical Directors Association, 2022, 23, 1721-1728.e19.	2.5	22
38	Need to improve thromboprophylaxis across the continuum of care for surgical patients. Advances in Therapy, 2010, 27, 81-93.	2.9	21
39	Venous Thromboembolism Pharmacy Intervention Management Program With an Active, Multifaceted Approach Reduces Preventable Venous Thromboembolism and Increases Appropriate Prophylaxis. Clinical and Applied Thrombosis/Hemostasis, 2012, 18, 45-58.	1.7	21
40	Predictive Value of the Present-On-Admission Indicator for Hospital-acquired Venous Thromboembolism. Medical Care, 2015, 53, e31-e36.	2.4	21
41	Healthcare resource burden associated with hyponatremia among patients hospitalized for heart failure in the US. Journal of Medical Economics, 2013, 16, 415-420.	2.1	20
42	Evaluation of medical costs associated with use of new oral anticoagulants compared with standard therapy among venous thromboembolism patients. Journal of Medical Economics, 2014, 17, 763-770.	2.1	20
43	When Patients Customize Nursing Home Ratings, Choices And Rankings Differ From The Government's Version. Health Affairs, 2016, 35, 714-719.	5.2	19
44	Management Strategies and Outcomes for Hyponatremia in Cirrhosis in the Hyponatremia Registry. Canadian Journal of Gastroenterology and Hepatology, 2018, 2018, 1-9.	1.9	19
45	Development and external validation of a prognostic tool for COVID-19 critical disease. PLoS ONE, 2020, 15, e0242953.	2.5	19
46	Influence of the duration of hospital length of stay on frequency of prophylaxis and risk for venous thromboembolism among patients hospitalized for acute medical illnesses in the USA. Drugs in Context, 2019, 8, 1-9.	2.2	19
47	Real-World Medical Cost Avoidance When New Oral Anticoagulants are Used Versus Warfarin for Venous Thromboembolism in the United States. Clinical and Applied Thrombosis/Hemostasis, 2016, 22, 5-11.	1.7	18
48	A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 911-920.	0.9	18
49	Improved outcomes over time for adult COVID-19 patients with acute respiratory distress syndrome or acute respiratory failure. PLoS ONE, 2021, 16, e0253767.	2.5	18
50	How to usethe core competencies in hospital medicine: A framework for curriculum development. Journal of Hospital Medicine, 2006, 1, 57-67.	1.4	17
51	Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors. Advances in Therapy, 2011, 28, 907-926.	2.9	17
52	Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials. Journal of Medical Economics, 2013, 16, 1163-1168.	2.1	17
53	Hypoglycemia-Related Hospitalizations and Mortality Among Patients With Diabetes Transitioning to Dialysis. American Journal of Kidney Diseases, 2018, 72, 701-710.	1.9	17
54	Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis. Thrombosis and Haemostasis, 2009, 102, 321-326.	3.4	16

#	Article	IF	CITATIONS
55	Rate of deep-vein thrombosis and pulmonary embolism during the care continuum in patients with acute ischemic stroke in the United States. BMC Neurology, 2013, 13, 17.	1.8	16
56	Real-world comparison of all-cause hospitalizations, hospitalizations due to stroke and major bleeding, and costs for non-valvular atrial fibrillation patients prescribed oral anticoagulants in a US health plan. Journal of Medical Economics, 2018, 21, 244-253.	2.1	16
57	Dialysis Provider and Outcomes among United States Veterans Who Transition to Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1055-1062.	4.5	15
58	Pneumonia readmissions: risk factors and implications. Ochsner Journal, 2014, 14, 649-54.	1.1	15
59	Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA. Future Microbiology, 2015, 10, 1049-1062.	2.0	14
60	Reducing the incidence of hospitalâ€associated venous thromboembolism within a network of academic hospitals: Findings from five <scp>U</scp> niversity of <scp>C</scp> alifornia medical centers. Journal of Hospital Medicine, 2016, 11, S22-S28.	1.4	14
61	Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare population. Journal of Thrombosis and Thrombolysis, 2019, 48, 240-249.	2.1	14
62	Estimated medical cost reductions associated with use of novel oral anticoagulants vs warfarin in a real-world non-valvular atrial fibrillation patient population. Journal of Medical Economics, 2014, 17, 771-781.	2.1	13
63	Efficacy and safety of sodium zirconium cyclosilicate in patients with baseline serum potassium level ≥ 5.5 mmol/L: pooled analysis from two phase 3 trials. BMC Nephrology, 2019, 20, 440.	1.8	12
64	Real-world comparison of in-hospital Reveal LINQ insertable cardiac monitor insertion inside and outside of the cardiac catheterization or electrophysiology laboratory. American Heart Journal, 2019, 207, 76-82.	2.7	12
65	Postoperative respiratory failure: An update on the validity of the Agency for Healthcare Research and Quality Patient Safety Indicator 11 in an era of clinical documentation improvement programs. American Journal of Surgery, 2020, 220, 222-228.	1.8	12
66	Are There Any Differences in the Clinical and Economic Outcomes Between US Cancer Patients Receiving Appropriate or Inappropriate Venous Thromboembolism Prophylaxis?. Journal of Oncology Practice, 2009, 5, 159-164.	2.5	11
67	Lack of Thromboprophylaxis Across the Care Continuum in US Medical Patients. Hospital Practice (1995), 2010, 38, 17-25.	1.0	11
68	Real-World Rates of In-hospital and Postdischarge Deep-Vein Thrombosis and Pulmonary Embolism in At-Risk Medical Patients in the United States. Clinical and Applied Thrombosis/Hemostasis, 2011, 17, 611-619.	1.7	11
69	Emergency Medicine and Hospital Medicine: A Call for Collaboration. American Journal of Medicine, 2012, 125, 826.e1-826.e6.	1.5	11
70	Estimated medical cost reductions associated with apixaban in real-world patients with non-valvular atrial fibrillation. Journal of Medical Economics, 2013, 16, 1193-1202.	2.1	11
71	Balancing Service and Education: An AAIM Consensus Statement. American Journal of Medicine, 2017, 130, 237-242.	1.5	11
72	Using an online quiz-based reinforcement system to teach healthcare quality and patient safety and care transitions at the University of California. International Journal for Quality in Health Care, 2017, 29, 735-739.	1.8	11

#	Article	IF	CITATIONS
73	Treatment patterns for patients hospitalized with chronic obstructive pulmonary disease. American Journal of Health-System Pharmacy, 2018, 75, 359-366.	1.0	11
74	Trends In Thromboprophylaxis Use In US Hospitals, 2006–2010. Blood, 2013, 122, 1707-1707.	1.4	11
75	Productive Interdisciplinary Team Relationships. Lippincott's Case Management: Managing the Process of Patient Care, 2006, 11, 160???164.	0.2	10
76	Inpatient and Outpatient Occurrence of Deep Vein Thrombosis and Pulmonary Embolism and Thromboprophylaxis Following Selected At-Risk Surgeries. Annals of Pharmacotherapy, 2011, 45, 1045-1052.	1.9	10
77	Lower 30-day readmission rates with roflumilast treatment among patients hospitalized for chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 909.	2.3	10
78	Patient Motivators for Emergency Department Utilization: A Pilot Cross-Sectional Survey of Uninsured Admitted Patients at a University Teaching Hospital. Journal of Emergency Medicine, 2015, 49, 203-210.e3.	0.7	10
79	Frequency of hospital readmissions for venous thromboembolism and associated hospital costs and length of stay among acute medically ill patients in the US. Journal of Medical Economics, 2019, 22, 1119-1125.	2.1	10
80	Hospitalized patients with acute decompensated heart failure: Recognition, risk stratification, and treatment review. Journal of Hospital Medicine, 2008, 3, S16-S24.	1.4	9
81	Appropriate VTE Prophylaxis is Associated with Lower Direct Medical Costs. Hospital Practice (1995), 2010, 38, 130-136.	1.0	9
82	Application of randomized clinical trial data to actual practice: apixaban therapy for reduction of stroke risk in non-valvular atrial fibrillation patients. Current Medical Research and Opinion, 2013, 29, 1253-1261.	1.9	9
83	Evaluation of medical costs avoided when new oral anticoagulants are used for extended treatment of venous thromboembolism based on clinical trial results. Journal of Thrombosis and Thrombolysis, 2015, 40, 131-138.	2.1	9
84	Realâ€World Use of Prophylactic Antibiotics in Insertable Cardiac Monitor Procedures. PACE - Pacing and Clinical Electrophysiology, 2016, 39, 837-842.	1.2	9
85	Contemporary NSTEMI management: the role of the hospitalist. Hospital Practice (1995), 2020, 48, 1-11.	1.0	9
86	Who Will Care for Our Hospitalized Patients?. Stroke, 2005, 36, 1113-1114.	2.0	8
87	A business of medicine curriculum for medical students. Medical Education, 2005, 39, 510-511.	2.1	8
88	Improving the management of patients after myocardial infarction, from admission to discharge. Clinical Therapeutics, 2006, 28, 1509-1539.	2.5	8
89	The Role of Hospitalists in the Acute Care of Stroke Patients. Current Treatment Options in Cardiovascular Medicine, 2010, 12, 240-249.	0.9	8
90	Temporal pattern and costs of rehospitalization in atrial fibrillation/atrial flutter patients with one or more additional risk factors. Journal of Medical Economics, 2012, 15, 548-555.	2.1	8

#	Article	IF	CITATIONS
91	Incremental Health Care Burden of Bleeding Among Patients with Venous Thromboembolism in the United States. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 965-972.	0.9	8
92	Rationale and study protocol for the Nursing Home Compare Plus (NHCPlus) randomized controlled trial: A personalized decision aid for patients transitioning from the hospital to a skilled-nursing facility. Contemporary Clinical Trials, 2016, 47, 139-145.	1.8	8
93	The Impact of Unmet Communication and Education Needs on Neurosurgical Patient and Caregiver Experiences of Care: A Qualitative Exploratory Analysis. World Neurosurgery, 2019, 122, e1528-e1535.	1.3	8
94	Stratifying Deterioration Risk by Acuity at Admission Offers Triage Insights for Coronavirus Disease 2019 Patients. , 2021, 3, e0400.		8
95	Who is managing acute decompensated heart failure? The need for a multidisciplinary approach. Journal of Hospital Medicine, 2008, 3, S1-S6.	1.4	7
96	CMS' Hospital-Acquired Conditions for the Neurohospitalist. Neurohospitalist, The, 2012, 2, 18-27.	0.8	7
97	Implementation of a Mandated Venous Thromboembolism Clinical Order Set Improves Venous Thromboembolism Core Measures. Hospital Practice (1995), 2014, 42, 89-99.	1.0	7
98	Venous Thromboembolism Prophylaxis and Risk in the Inpatient and Outpatient Continuum of Care Among Hospitalized Acutely III Patients in the US: A Retrospective Analysis. Advances in Therapy, 2019, 36, 59-71.	2.9	7
99	A systems-based practice curriculum. Medical Education, 2004, 38, 568-569.	2.1	6
100	Therapeutic Interchange of Parenteral Anticoagulants: Challenges for Pharmacy and Therapeutics Committees. Pharmaceuticals, 2011, 4, 1475-1487.	3.8	6
101	Correlation of Simulation Examination to Written Test Scores for Advanced Cardiac Life Support Testing: Prospective Cohort Study. Western Journal of Emergency Medicine, 2015, 16, 907-912.	1.1	6
102	Identifying Solutions to Ambulatory Faculty Recruitment, Retention, and Remuneration in Graduate Medical Education: An AAIM Position Paper. American Journal of Medicine, 2020, 133, 386-394.	1.5	6
103	Awareness, Knowledge, and Utility of RCT Data vs RWE: Results From a Survey of US Cardiologists: Real-world Evidence in Clinical Decision Making. Clinical Medicine Insights: Cardiology, 2020, 14, 117954682095341.	1.8	6
104	IS IT TIME FOR NEUROHOSPITALISTS?. Neurology, 2009, 72, 476-477.	1.1	5
105	Comparison of Medical Costs of Patients With Atrial Fibrillation Unsuitable for Warfarin Treatment With Apixaban or Aspirin Based on AVERROES Trial. Clinical and Applied Thrombosis/Hemostasis, 2015, 21, 235-240.	1.7	5
106	Venous Thromboembolism Prophylaxis and Risk for Acutely Medically Ill Patients Stratified by Different Ages and Renal Disease Status. Clinical and Applied Thrombosis/Hemostasis, 2019, 25, 107602961882328.	1.7	5
107	Impact of a Central-Line Insertion Site Assessment (CLISA) score on localized insertion site infection to prevent central-line–associated bloodstream infection (CLABSI). Infection Control and Hospital Epidemiology, 2020, 41, 59-66.	1.8	5
108	A Real-World Observational Study of Hospitalization and Health Care Costs Among Nonvalvular Atrial Fibrillation Patients Prescribed Oral Anticoagulants in the U.S. Medicare Population. Journal of Managed Care & Specialty Pharmacy, 2020, 26, 639-651.	0.9	5

#	Article	IF	CITATIONS
109	The Impact of COVID-19 on Volume of Inpatient Hospitalization Through General Medicine and Medicine Subspecialty Services at US Medical Centers. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2021, 5, 516-519.	2.4	5
110	Hospital Discharge and Selecting a Skilled Nursing Facility. Professional Case Management, 2018, 23, 50-59.	0.4	5
111	Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis. Clinical Drug Investigation, 2021, 41, 941-953.	2.2	5
112	Real-World Analysis of Venous Thromboembolism Rates and Thromboprophylaxis Prescribing In US Patients with Cancer Blood, 2010, 116, 3802-3802.	1.4	5
113	Choosing Non-Vitamin K Antagonist Oral Anticoagulants: Practical Considerations We Need to Know. Ochsner Journal, 2016, 16, 531-541.	1.1	5
114	Mortality, healthcare resource utilization, and cost among Medicare beneficiaries with <i>Clostridioides difficile</i> infection with and without sepsis. Therapeutic Advances in Infectious Disease, 2022, 9, 204993612210956.	1.8	5
115	The Role of Hospitalists in the Management of Acute Decompensated Heart Failure. The American Heart Hospital Journal, 2005, 3, 111-117.	0.2	4
116	Health Care-Associated Pneumonia. Hospital Practice (1995), 2010, 38, 63-74.	1.0	4
117	Relationship of hospital-associated bleeding with length of stay and total hospitalization costs in patients hospitalized for atrial fibrillation. Journal of Medical Economics, 2016, 19, 490-496.	2.1	4
118	Platelet response to direct thrombin inhibitor or fondaparinux treatment in patients with suspected heparin-induced thrombocytopenia. Journal of Thrombosis and Thrombolysis, 2018, 45, 536-542.	2.1	4
119	Tackling the Problem of Ambulatory Faculty Recruitment in Undergraduate Medical Education: An AAIM Position Paper. American Journal of Medicine, 2019, 132, 1242-1246.	1.5	4
120	Costs associated with unplanned readmissions among patients with heart failure with and without hyponatremia. American Journal of Health-System Pharmacy, 2019, 76, 374-380.	1.0	4
121	Continuous glucose monitoring in an endâ€stage renal disease patient with diabetes receiving hemodialysis. Seminars in Dialysis, 2021, 34, 388-393.	1.3	4
122	Recommendations for management of community- and hospital-acquired pneumonia—the hospitalist perspective. Current Opinion in Pulmonary Medicine, 2004, 10, S23-S27.	2.6	3
123	Optimizing Delivery of Care for Patients with MRSA Infection: Focus on Transitions of Care. Hospital Practice (1995), 2011, 39, 18-31.	1.0	3
124	Developing Faculty in Emerging Areas of Interdisciplinary Research. American Journal of Medicine, 2018, 131, 1257-1262.	1.5	3
125	Mortality Risk in Chronic Kidney Disease Patients Transitioning to Dialysis: Impact of Opiate and Non-Opiate Use. American Journal of Nephrology, 2020, 51, 715-725.	3.1	3
126	Novel therapeutic approaches for COVID-19 in chronic kidney disease and transplant. Current Opinion in Nephrology and Hypertension, 2021, 30, 47-53.	2.0	3

#	Article	IF	CITATIONS
127	Infections in hospitalized patients: what is happening and who can help?. Cleveland Clinic Journal of Medicine, 2007, 74, S2-S2.	1.3	3
128	In-hospital mortality, length of stay, and hospitalization cost of COVID-19 patients with and without hyperkalemia. American Journal of the Medical Sciences, 2022, 364, 444-453.	1.1	3
129	Outcomes and risk factors for delayed-onset postoperative respiratory failure: a multi-center case-control study by the University of California Critical Care Research Collaborative (UC3RC). BMC Anesthesiology, 2022, 22, 146.	1.8	3
130	A successful hospitalist rotation for senior medicine residents. Medical Education, 2003, 37, 1042-1042.	2.1	2
131	Identifying strategies to improve outcomes and reduce costs—a role for the hospitalist. Current Opinion in Pulmonary Medicine, 2004, 10, S19-S22.	2.6	2
132	Risk Factors Associated With Early Postoperative Respiratory Failure: A Matched Case-Control Study. Journal of Surgical Research, 2021, 261, 310-319.	1.6	2
133	An innovative advanced patientâ^'doctor course for medical students. Medical Education, 2005, 39, 518-519.	2.1	1
134	Update in Hospital Medicine. Annals of Internal Medicine, 2007, 147, 628.	3.9	1
135	Prevention of venous thromboembolism in cancer patients: current approaches and opportunities for improvement. Oncology Reviews, 2011, 5, 191-204.	1.8	1
136	Rationale for Upstream Dual Antiplatelet Therapy in Non-ST-Segment Elevation Myocardial Infarction. Current Emergency and Hospital Medicine Reports, 2014, 2, 76-89.	1.5	1
137	Impact of roflumilast on exacerbations of COPD, health care utilization, and costs in a predominantly elderly Medicare Advantage population. International Journal of COPD, 2015, 10, 565.	2.3	1
138	Target-specific oral anticoagulants and the hospitalist. Hospital Practice (1995), 2015, 43, 1-12.	1.0	1
139	Balancing Anti-thrombotic Efficacy and Bleeding Risk in the Contemporary Management of Venous Thromboembolism. Current Emergency and Hospital Medicine Reports, 2015, 3, 89-99.	1.5	1
140	Impact of a Standardized Central Line Insertion Site Assessment Score on Localized Inflammation and Infection. Open Forum Infectious Diseases, 2016, 3, .	0.9	1
141	Appropriate Red Blood Cell Transfusion Utilization Among Hospitalized Medical Patients. Current Emergency and Hospital Medicine Reports, 2016, 4, 184-191.	1.5	1
142	What Hospitalists Need to Know About Quality Improvement. Current Emergency and Hospital Medicine Reports, 2017, 5, 109-113.	1.5	1
143	Rates of Guideline-Recommended Venous Thromboembolism Prophylaxis in Surgical Patients among US Hospitals: A Real-World Analysis Blood, 2007, 110, 1865-1865.	1.4	1
144	Managing hospitalized patients with a COPD exacerbation: the role of hospitalists and the multidisciplinary team. Postgraduate Medicine, 2022, 134, 152-159.	2.0	1

#	Article	IF	CITATIONS
145	Community- and hospital-acquired pneumonia—the role of the hospitalist in improving outcomes and reducing resource utilization. Current Opinion in Pulmonary Medicine, 2004, 10, S1-S2.	2.6	0
146	New Options for Anticoagulation Following Total Hip Arthroplasty and Total Knee Arthroplasty: New Oral Agents on the Horizon. Hospital Practice (1995), 2012, 40, 19-26.	1.0	0
147	How to Develop and Validate Institutional ACS Protocols: Guidelines and Transitions of Care in ACS Management. Current Emergency and Hospital Medicine Reports, 2014, 2, 69-75.	1.5	0
148	The Impact of Risk Stratification of Venous Thromboembolism on Complexity and Site of Management. Current Emergency and Hospital Medicine Reports, 2015, 3, 100-108.	1.5	0
149	Role of hospitalists in the diagnosis of atrial fibrillation for the management of cryptogenic stroke patients. Hospital Practice (1995), 2016, 44, 274-278.	1.0	0
150	Hospital Readmissions in Pneumonia Patients: Quality of Care and Cost Containment. Current Emergency and Hospital Medicine Reports, 2016, 4, 172-176.	1.5	0
151	Antimicrobial Stewardship: The Role of Hospitalists and the Emergency Department. Current Emergency and Hospital Medicine Reports, 2016, 4, 177-183.	1.5	0
152	Evidence-Based Medicine and the Art of Medicine. Current Emergency and Hospital Medicine Reports, 2017, 5, 157-161.	1.5	0
153	Closing the Clinical Knowledge Gap: Achieving Collaborative Nursing Education Between Hospitalists and Nurses. Current Emergency and Hospital Medicine Reports, 2017, 5, 114-118.	1.5	0
154	Utilization and budget impact of tolvaptan in the inpatient setting among patients with heart failure and hyponatremia. Current Medical Research and Opinion, 2018, 34, 559-566.	1.9	0
155	Venous Thromboembolism Rates in Transferred Patients: A Cross-Sectional Study. Journal of General Internal Medicine, 2018, 33, 42-49.	2.6	0
156	Alternatives to Care in Physician Offices: Patients' Expectations and Satisfaction. Journal of General Internal Medicine, 2018, 33, 1598-1600.	2.6	0
157	When to Switch Therapy in Patients with Severe Community-Acquired Pneumonia. Annals of Internal Medicine, 2008, 148, 625.	3.9	0
158	Real-World Analysis of the Duration of Risk of Venous Thromboembolism In US Surgical Patients. Blood, 2010, 116, 479-479.	1.4	0
159	Prevention of Deep Vein Thrombosis In Patients In the United States with Infectious Diseases. Blood, 2010, 116, 4389-4389.	1.4	0
160	Comparison of Medical Costs Avoided When New Oral Anticoagulants Are Used for the Treatment of Patients with Atrial Fibrillation and Venous Thromboembolism in the U.S. Blood, 2014, 124, 2181-2181.	1.4	0
161	Evaluation of Differences in Medical Costs Associated with Venous Thromboembolism Prophylaxis with Desirudin Vs. Low Molecular Weight Heparin Among Patients Undergoing Total Hip Replacement Surgery. Blood, 2014, 124, 4852-4852.	1.4	0
162	Estimate of Real-World Medical Costs Avoidance When New Oral Anticoagulants Are Used Vs. Standard Therapy for the Treatment of Patients with Venous Thromboembolism in the U.S. Blood, 2014, 124, 687-687.	1.4	0

#	Article	IF	CITATIONS
163	Development and external validation of a prognostic tool for COVID-19 critical disease. , 2020, 15, e0242953.		0
164	Development and external validation of a prognostic tool for COVID-19 critical disease. , 2020, 15, e0242953.		0
165	Development and external validation of a prognostic tool for COVID-19 critical disease. , 2020, 15, e0242953.		Ο
166	Development and external validation of a prognostic tool for COVID-19 critical disease. , 2020, 15, e0242953.		0